Brief: Ryvu Therapeutics Signs Deal To Support Clinical Trials For BioNTech’s Investigational Cancer Immunotherapies In Poland

Ryvu Therapeutics SA

02/09/2025 07:12

Corrects source company in the body of the brief to Ryvu Therapeutics from BioNTech

Sept 2 (Reuters) - Ryvu Therapeutics RVU.WA:

CONCLUSION OF STRATEGIC AGREEMENT WITH BIONTECH SE TO SUPPORT CLINICAL TRIALS FOR BIONTECH’S INVESTIGATIONAL CANCER IMMUNOTHERAPIES IN POLAND

TOTAL BUDGET FOR ORDERS TO RYVU AT 2.95 MILLION EUR

AGREEMENT IS OF FRAMEWORK NATURE, AND INDIVIDUAL SERVICES WILL BE PERFORMED BY RYVU BASED ON INDEPENDENT ORDERS SUBMITTED BY BIONTECH

ORDERS SUPPORT BIONTECH IN ACTIVITIES AIMED AT ACCELERATING ACTIVATION OF CENTERS AND PATIENT RECRUITMENT FOR SEVERAL KEY CLINICAL PROGRAMS IN  FIELD OF ONCOLOGY, IMPLEMENTED BY BIONTECH IN POLAND

AGREEMENT EXPANDS EXISTING COLLABORATION WITH BIONTECH

Source text: ID:nEM26NnKba

Further company coverage: RVU.WA [22UAy.DE]

 (Gdansk Newsroom)

 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))